PSG
TTNP

Planning Solutions Group’s Titan Pharmaceuticals TTNP Stock Holding History

Planning Solutions Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4
Closed -$3K – 138
2018
Q4 		$3K Buy
+4
New +$4.49K ﹤0.01% 122

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Planning Solutions Group's TTNP Position: Q1 2019 in Review

Planning Solutions Group sold out of Titan Pharmaceuticals (TTNP) in Q1 2019, closing a stake of 4 shares — an estimated $3K sold.

Planning Solutions Group first reported a position in TTNP in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 15 funds tracked by Wall St. Rank hold TTNP as of Q1 2019.

  • Planning Solutions Group reported no remaining Titan Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Planning Solutions Group sold 4 Titan Pharmaceuticals shares in Q1 2019, an estimated $3K.
  • Planning Solutions Group first reported a position in Titan Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Planning Solutions Group's Titan Pharmaceuticals position peaked at $3K in Q4 2018.
  • 15 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2019.

Based on Planning Solutions Group's 13F filing for Q1 2019, filed 10 May 2019.